European Neuropsychopharmacology
Volume 20, Issue 11 , Pages 823-828 , November 2010

A double-blind, placebo-controlled study of N-acetyl cysteine plus naltrexone for methamphetamine dependence

Received 13 May 2010 ,Revised 21 June 2010 ,Accepted 25 June 2010.

References 

  1. Batki, S.L., Moon, J., Bradley, M., et al., 1999. Fluoxetine in methamphetamine dependence—a controlled trial: preliminary analysis. in: L.S. Harris, ed. Problems of Drug Dependence 1999. Proceedings of the 61st Annual Scientific Meeting of the College on Problems of Drug Dependence, Inc. US Government Printing Office. 2000:235. NIDA research monograph 180, NIH publication 00-4737, Washington, DC.
  2. Berigan TR, Russell ML. Treatment of methamphetamine cravings with bupropion: a case report. Prim. Care. Companion J. Clin. Psychiatry. 2001;3:267–268
  3. First, M.B., Spitzer, R.L., Gibbon, M., Williams, J.B.W. 1995. Structured Clinical Interview for DSM-IV-Patient Edition (SCID-I/P, Version 2.0). Biometrics Research Department, New York State Psychiatric Institute, New York.
  4. Flannery BA, Volpicelli JR, Pettinati HM. Psychometric properties of the Penn Alcohol Craving Scale. Alcohol. Clin. Exp. Res. 1999;23:1289–1295
  5. Frisch MB, Cornell J, Villaneuva M. Clinical validation of the Quality of Life Inventory: a measure of life satisfaction for use in treatment planning and outcome assessment. Psychol. Assess. 1993;4:92–101
  6. Galloway GP, Newmeyer J, Knapp T, Stalcup SA, Smith D. A controlled trial of imipramine for the treatment of methamphetamine dependence. J. Subst. Abuse Treat. 1996;13:493–497
  7. Gass JT, Olive MF. Glutamatergic substrates of drug addiction and alcoholism. Biochem. Pharmacol. 2008;75:218–265
  8. Grant JE, Odlaug BL, Kim SW. A double-blind, placebo-controlled trial of a glutamate modulating agent, N-acetyl cysteine, in the treatment of trichotillomania. Arch. Gen. Psychiatry. 2009;66(7):756–763
  9. Guy W. ECDEU Assessment Manual for Psychopharmacology. In: US Dept Health, Education and Welfare Publication (ADM) 76-338. Rockville: National Institute of Mental Health; 1976;p. 218–222
  10. Hamilton M. The assessment of anxiety states by rating. Br. J. Med. Psychiatry. 1959;32:50–55
  11. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry. 1960;23:56–62
  12. Heinzerling KG, Shoptaw S, Peck JA, Yang X, Liu J, Roll J, et al. Randomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2006;85:177–184
  13. Ikemoto S, Glazier BS, Murphy JM, McBride WJ. Role of dopamine D1 and D2 receptors in the nucleus accumbens in mediating reward. J. Neurosci. 1997;17:8580–8587
  14. Jayaram-Lindström N, Hammarberg A, Beck O, Franck J. Naltrexone for the treatment of amphetamine dependence: a randomized, placebo-controlled trial. Am. J. Psychiatry. 2008;165:1442–1448
  15. Kim SW, Grant JE, Adson DE, Shin YC. Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry. 2001;49:914–921
  16. LaRowe SD, Mardikian P, Malcolm R, Myrick H, Kalivas P, McFarland K, et al. Safety and tolerability of N-acetylcysteine in cocaine-dependent individuals. Am. J. Addict. 2006;15:105–110
  17. LaRowe SD, Myrick H, Hedden S, Mardikian P, Saladin M, McRae A, et al. Is cocaine desire reduced by N-acetylcysteine?. Am. J. Psychiatry. 2007;164:1115–1117
  18. Lee NK, Rawson RA. A systematic review of cognitive and behavioural therapies for methamphetamine dependence. Drug Alcohol Rev. 2008;27:309–317
  19. McFarland K, Lapish CC, Kalivas PW. Prefrontal glutamate release into the core of the nucleus accumbens mediates cocaine-induced reinstatement of drug-seeking behavior. J. Neurosci. 2003;23:3531–3537
  20. Meredith CW, Jaffe C, Ang-Lee K, Saxon AJ. Implications of chronic methamphetamine use: a literature review. Harv. Rev. Psychiatry. 2005;13:141–154
  21. Newton TF, Roache JD, De La Garza RII, Fong T, Wallace CL, Li SH, et al. Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving. Neuropsychopharmacology. 2006;31:1537–1544
  22. Phillips AG, LePiane FG. Reinforcing effects of morphine microinjection onto the ventral tegmental area. Pharmacol. Biochem. Behav. 1980;12:965–968
  23. Piasecki MP, Steinagel GM, Thienhaus OJ, Kohlenberg BS. An exploratory study: the use of paroxetine for methamphetamine craving. J. Psychoactive Drugs. 2002;34:301–304
  24. Roll JM, Petry NM, Stitzer ML, Brecht ML, Peirce JM, McCann MJ, et al. Contingency management for the treatment of methamphetamine use disorders. Am. J. Psychiatry. 2006;163:1993–1999
  25. Rose ME, Grant JE. Pharmacotherapy for methamphetamine dependence: a review of the pathophysiology of methamphetamine addiction and the theoretical basis and efficacy of pharmacotherapeutic interventions. Ann. Clin. Psychiatry. 2008;20:145–155
  26. Sheehan DV. The Anxiety Disease. New York: Scribner's; 1983;
  27. Shoptaw S, Heinzerling KG, Rotheram-Fuller E, Steward T, Wang J, Swanson AN, et al. Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2008;96:222–232
  28. van Wolfswinkel L, van Ree JM. Effects of morphine and naloxone on thresholds of ventral tegmental electrical self-stimulation. Naunyn. Schmiedebergs. Arch. Pharmacol. 1985;330:84–92

PII: S0924-977X(10)00145-8

doi: 10.1016/j.euroneuro.2010.06.018

European Neuropsychopharmacology
Volume 20, Issue 11 , Pages 823-828 , November 2010

Article Tools

* Image Usage & Resolution